Jeroen J. W. M. Janssen

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 467 citations · Full text

Medicine, Oncology, Pharmacology +9

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin

Baoxu Pang, Xiaohang Qiao, Lennert Janssen et al. · Nature Communications · 2013 · 431 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Michael Heuser, Yishai Ofran, Nicolas Boissel et al. · Annals of Oncology · 2020 · 284 citations · Full text

Medicine, Hematology, Oncology +16

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

Evelien Kneppers, Bronno van der Holt, Marie José Kersten et al. · Blood · 2011 · 193 citations · Full text

Medicine, Hematology, Oncology +16